-- Company reports strong growth in revenue,
EBITDA¹ and net income, excluding prior-year one-time,
non-cash gain --
TORONTO, March 2,
2023 /CNW/ - Andlauer Healthcare Group Inc.
(TSX: AND) ("AHG" or the "Company") today reported its financial
results for the three-month period ("Q4 2022") and year ended
December 31, 2022 ("Fiscal
2022").
Q4 2022 Summary
- Revenue increased 24.6% to $165.8
million, compared to $133.0
million for the three-month period ended December 31, 2021 ("Q4 2021");
- Operating income increased 31.3% to $28.2 million, compared to $21.5 million in Q4 2021;
- Net income totaled $19.8 million
in Q4 2022, compared to $53.1
million, or $15.2 million
excluding the one-time, non-cash gain of $37.9 million on the step acquisition of Skelton
USA (the "gain on step
acquisition"), in Q4 2021;
- Total comprehensive income was $17.1
million in Q4 2022 compared to $56.0
million, or $18.1 million
excluding the gain on step acquisition, in Q4 2021;
- EBITDA was $44.7 million in Q4
2022 compared to $73.7 million, or
$35.8 million excluding the gain on
step acquisition, in Q4 2021;
- EBITDA Margin was 27.0% in Q4 2022, compared to 55.4% or 26.9%,
excluding the gain on step acquisition in Q4 2021; and
- AHG continued to provide logistics and distribution,
specialized transportation, and packaging solutions to certain of
its manufacturer, 3PL provider, wholesaler and government clients
that are involved in the Canadian supply of COVID-19 vaccines and
ancillary products. In Q4 2022, the Company's COVID-19
vaccine-related revenue comprised approximately 2.3% of total
revenue, compared to approximately 5.2% in Q4 2021.
Fiscal 2022 Summary
- Revenue increased 47.3% to $648.4
million, compared to $440.1
million for the year ended December
31, 2021 ("Fiscal 2021");
- Operating income increased 49.7% to $110.3 million, compared to $73.7 million in Fiscal 2021;
- Net income was $76.3 million in
Fiscal 2022, compared to $90.0
million, or $52.0 million
excluding the gain on step acquisition, in Fiscal 2021;
- Total comprehensive income was $91.0
million in Fiscal 2022, compared with $92.8 million, or $54.9
million excluding the gain on step acquisition, in Fiscal
2021;
- EBITDA was $174.5 million in
Fiscal 2022, compared to $157.2
million, or $119.3 million
excluding the gain on step acquisition, in Fiscal 2021;
- EBITDA Margin was 26.9% in Fiscal 2022, compared to 35.7%, or
27.1% excluding the gain on step acquisition, in Fiscal 2021;
- During Fiscal 2022, approximately 3.0% of total revenue was
derived from AHG clients that are involved in the Canadian supply
of COVID-19 vaccines compared with approximately 4.0% in Fiscal
2021; and
- On March 1, 2022, AHG acquired
100% of the issued and outstanding shares of Logistics Support Unit
(LSU) Inc. ("LSU") for consideration of
approximately $26.7 million.
LSU is a third-party logistics provider
offering specialty pharmacy, warehousing, distribution and order
management services throughout Canada to national and international companies
as well as government clients in the pharmaceutical, medical and
biotechnology sectors.
"Since our first full year as a public company in 2020, our
revenue and net earnings have both more than doubled, reflecting
our success in delivering value to customers and capitalizing on
growth opportunities," said Michael
Andlauer, Chief Executive Officer of AHG. "With multiple
opportunities to strengthen our platform through the addition of
complementary services or strategic acquisitions, we expect to
continue to better serve our customers and generate strong returns
for our shareholders."
Selected Consolidated Financial Summary
|
Three
months
ended December
31,
|
|
Year
ended
December
31,
|
|
($CAD 000s, except
per share
amounts)
|
2022
|
2021
|
Variance
|
2022
|
2021
|
Variance
|
Revenue
|
|
|
|
|
|
|
Logistics &
distribution
|
37,911
|
29,521
|
28.4 %
|
155,575
|
115,255
|
35.0 %
|
Packaging
solutions
|
3,925
|
4,351
|
(9.8) %
|
21,290
|
20,072
|
6.1 %
|
Healthcare Logistics
segment
|
41,836
|
33,872
|
23.5 %
|
176,865
|
135,327
|
30.7 %
|
Ground
transportation
|
113,057
|
85,268
|
32.6 %
|
422,236
|
261,870
|
61.2 %
|
Air freight
forwarding
|
7,549
|
10,024
|
(24.7) %
|
34,383
|
29,214
|
17.7 %
|
Dedicated and last
mile delivery
|
17,354
|
14,282
|
21.5 %
|
66,896
|
52,260
|
28.0 %
|
Intersegment
revenue
|
(14,024)
|
(10,421)
|
34.6 %
|
(51,957)
|
(38,556)
|
34.8 %
|
Specialized
Transportation segment
|
123,936
|
99,153
|
25.0 %
|
471,558
|
304,788
|
54.7 %
|
Total
revenue
|
165,772
|
133,025
|
24.6 %
|
648,423
|
440,115
|
47.3 %
|
Operating
expenses
|
137,606
|
111,573
|
23.3 %
|
538,078
|
366,412
|
46.9 %
|
Operating
income
|
28,166
|
21,452
|
31.3 %
|
110,345
|
73,703
|
49.7 %
|
Gain on step
acquisition
|
-
|
37,921
|
N/A
|
-
|
37,921
|
N/A
|
Net
income
|
19,824
|
53,104
|
(62.6) %
|
76,275
|
89,954
|
(15.2) %
|
Foreign currency translation
adjustment
|
(2,772)
|
2,889
|
N/A
|
14,743
|
2,889
|
410.3 %
|
Total comprehensive
income
|
17,052
|
55,993
|
(69.5) %
|
91,018
|
92,843
|
(2.0) %
|
Earnings per share –
basic
|
$ 0.47
|
$ 1.29
|
($ 0.82)
|
$ 1.82
|
$ 2.30
|
($ 0.48)
|
Earnings per share –
diluted
|
$ 0.46
|
$ 1.26
|
($ 0.80)
|
$ 1.79
|
$ 2.25
|
($ 0.46)
|
Select financial
metrics
|
|
|
|
|
|
|
EBITDA¹
|
44,684
|
73,691
|
(39.4 %)
|
174,469
|
157,177
|
11.0 %
|
EBITDA
Margin¹
|
27.0 %
|
55.4 %
|
(2840 bps)
|
26.9 %
|
35.7 %
|
(880 bps)
|
EBITDA¹ excluding
gain
on step
acquisition
|
44,684
|
35,770
|
24.9 %
|
174,469
|
119,256
|
46.3 %
|
EBITDA Margin¹
excluding gain
on step
acquisition
|
27.0 %
|
26.9 %
|
10 bps
|
26.9 %
|
27.1 %
|
(20 bps)
|
Q4 2022 Financial Results
Revenue for Q4 2022 increased by 24.6% to $165.8 million, compared with $133.0 million in Q4 2021. The acquisitions of
LSU, Skelton USA Inc. ("Skelton USA") and T.F. Boyle Transportation, Inc.
("Boyle Transportation") accounted for approximately $17.6 million of the $32.7
million increase, with the remaining growth attributable to
organic growth and fuel surcharge revenue as described below. The
Company's COVID-19 vaccine-related revenue comprised approximately
2.3% of total revenue in Q4 2022, compared to approximately 5.2% in
Q4 2021. AHG expects that revenues relating to COVID-19 vaccines
and ancillary products may continue to decrease in Fiscal 2023 and
does not foresee a return to similar levels of activity in this
space as that experienced in Fiscal 2021.
Revenue for the healthcare logistics segment totaled
$41.8 million, an increase of 23.5%,
or approximately $7.9 million,
compared with Q4 2021. The increase was primarily attributable to
the 28.4% year-over-year growth in the Company's logistics and
distribution product line revenue, reflecting greater outbound
order handling activities for Accuristix, increases in
transportation billings impacted by fuel surcharge programs from
carriers, which are passed on to customers, and $2.4 million in incremental revenue from the
acquisition of LSU, net of year-to-date
pass-through expenses classified as billings to LSU customers. The overall increase in segment
revenue was partially offset by a 9.8% year-over-year decline in
AHG's packaging solutions revenue, reflecting lower volume from one
of the Company's larger packaging customers due to component supply
chain constraints by their suppliers.
Revenue in the specialized transportation segment totaled
$123.9 million, an increase of 25.0%,
or approximately $24.8 million,
compared with Q4 2021. The increase was attributable to: 32.6%
growth in the Company's ground transportation product line driven
by incremental revenue from the Boyle Transportation and Skelton
USA acquisitions of approximately
$15.2 million, organic growth, and
higher fuel costs passed on to customers as a component of pricing.
AHG's dedicated and last mile delivery product line also
contributed to segment growth, with a 21.5%, or $3.1 million, year-over-year increase in revenue,
reflecting ongoing route expansion and increases in fuel costs
passed on to customers. The overall increase in segment
revenue was partially offset by a 24.7%, or $2.5 million, year-over-year decline in AHG's air
freight forwarding revenue. Air freight forwarding revenue was
unusually high in Q4 2021 as the Company's clients attempted to
minimize service disruptions in British
Columbia arising from weather events that occurred in
November 2021, which severed regional
road and rail links to Vancouver
due to flooding and landslides. The Company's air freight
forwarding volumes returned to normal levels during Q1 2022.
Cost of transportation and services was $86.3
million, or 52.1% of revenue,
compared with $65.7 million, or 49.4% of revenue, for Q4
2021. The higher cost of transportation and services for Q4 2022
was primarily attributable to the impact of the acquisitions of
Boyle Transportation and Skelton USA over a full quarter, compared to two
months in Q4 2021, and higher fuel costs in line with the increases
in revenue related to fuel prices.
Direct operating expenses were $21.0 million, or 12.7% of revenue, compared with
$21.3 million, or 16.0% of revenue,
for Q4 2021. Direct operating expenses in Q4 2022 reflect outbound
volume growth in AHG's Accuristix logistics and distribution
operations, the acquisition of LSU on
March 1, 2022, and a year-to-date
reclassification of certain pass-through expenses to logistics and
distribution billings for LSU in
accordance with IFRS 15.
Selling, general and administrative ("SG&A") expenses were
$13.8 million, or 8.3% of revenue,
compared with $10.9 million, or 8.2%
of revenue, for Q4 2021. The increase reflects the impact of the
acquisitions of Boyle Transportation and Skelton USA over a full quarter, and LSU.
Operating income totaled $28.2
million, an increase of $6.7
million, or 31.3%, compared to $21.5
million for Q4 2021. Approximately $1.3 million of the increase was attributable to
the acquisitions of LSU, Boyle
Transportation and Skelton USA,
with the remainder attributable to organic growth.
Net income was $19.8 million, or
$0.46 per share (diluted), compared
with $53.1 million, or $1.26 per share (diluted), in Q4 2021. Net
income, excluding the gain on step acquisition, for Q4 2021 was
$15.2 million. Higher segment net
income before eliminations for both the Company's healthcare
logistics and specialized transportation operating segments
contributed to the increased profit on a consolidated basis when
excluding the gain on step acquisition.
Total comprehensive income was $17.1
million, compared to $56.0
million, or $18.1 million
excluding the gain on step acquisition in Q4 2021. Total
comprehensive income differs from net income due to the acquisition
of foreign operations (Boyle Transportation and Skelton
USA), which resulted in a negative
foreign currency translation adjustment of $2.8 million in Q4 2022 compared to a positive
foreign currency translation adjustment of $2.9 million in Q4 2021.
Earnings before interest, taxes, depreciation and amortization
("EBITDA")¹ totaled $44.7 million
compared with $73.7 million, or
$35.8 million excluding the gain on
step acquisition for Q4 2021. The increase (when excluding the gain
on step acquisition) is due to the factors discussed above and
reflects the incremental contributions from acquisitions and
organic growth in both of the Company's operating segments. EBITDA
Margin¹ was 27.0%, compared to 55.4%, or 26.9% excluding the gain
on step acquisition in Q4 2021.
2022 Financial Results
Revenue for Fiscal 2022 increased by 47.3% to $648.4 million, compared with $440.1 million in Fiscal 2021. The acquisitions
of LSU, Boyle Transportation and
Skelton USA accounted for
approximately $151.4 million of the
$208.3 million increase.
Revenue for the healthcare logistics segment totaled
$176.9 million, an increase of 30.7%,
or approximately $41.5 million,
compared with Fiscal 2021. The increase was primarily attributable
to the 35.0% year-over-year growth in the Company's logistics and
distribution product line revenue, reflecting $21.3 million in incremental revenue from the
acquisition of LSU, volume growth
within AHG's existing client base and rate increases primarily
related to transportation billings impacted by fuel surcharge
programs from carriers. AHG's packaging solutions also contributed
to this segment's revenue growth, with a 6.1% year-over-year
increase in revenue.
Revenue in the specialized transportation segment totaled
$471.6 million, an increase of 54.7%
compared with Fiscal 2021. The increase was attributable to 61.2%
growth in the Company's ground transportation product line driven
by incremental revenue from the Boyle Transportation and Skelton
USA acquisitions of approximately
$112.5 million, organic growth, and
higher fuel costs passed on to customers as a component of pricing.
AHG's air freight forwarding and dedicated and last mile delivery
product lines also contributed to segment growth with
year-over-year revenue increases of 17.7% and 28.0%, respectively.
The increase in air freight forwarding revenue reflects volume
growth and fuel-related revenue driven by increased fuel
surcharges. Growth in dedicated and last mile revenue reflects
ongoing route expansion and increases in fuel costs passed on to
customers.
Cost of transportation and services for Fiscal 2022 was
$322.8 million, or 50.0% of revenue,
compared with $201.8 million, or
46.0% of revenue, for Fiscal 2021. The increase is primarily
attributable to the acquisitions of Boyle Transportation and
Skelton USA, which were
consolidated for all of Fiscal 2022 versus only two months in
Fiscal 2021. The increase in the operating ratio for Fiscal 2022 as
compared to Fiscal 2021 is primarily attributable to higher fuel
costs for Fiscal 2022 in line with the increase in ground
transportation revenue related to fuel for Fiscal 2022.
Direct operating expenses for Fiscal 2022 were $102.3 million, or 15.8% of revenue, compared
with $84.9 million, or 19.3% of
revenue, for Fiscal 2021. Approximately $7.0
million of the $17.4 million
increase is attributable to the LSU
acquisition, with the remaining increase attributable to increased
volumes of inbound and outbound receiving and shipping volumes at
Accuristix. AHG's specialized transportation acquisitions (Boyle
Transportation and Skelton USA)
have lower facility-related costs compared to our healthcare
logistics segment, which resulted in a lower direct operating
expense operating ratio in Fiscal 2022 as compared to Fiscal
2021.
SG&A expenses for Fiscal 2022 were $48.5 million, or 7.5% of revenue, compared with
$37.1 million, or 8.4% of revenue,
for Fiscal 2021. The increase is primarily attributable to the
acquisitions of LSU, Boyle
Transportation and Skelton USA.
The decrease in SG&A expenses as a percentage of revenue
reflects operating leverage generated within SG&A functions
compared to revenue growth.
Operating income totaled $110.3
million, an increase of $36.6
million, or 49.7%, compared to $73.7
million for Fiscal 2021. Approximately $14.3 million of the increase was attributable to
the acquisitions of LSU, Boyle
Transportation and Skelton USA,
with the remainder attributable to organic growth.
Net income was $76.3 million, or
$1.79 per share (diluted), compared
with $90.0 million, or $2.25 per share (diluted), in Fiscal 2021. Net
income, excluding the gain on step acquisition, for Fiscal 2021 was
$52.0 million. Higher segment net
income before eliminations for both the Company's healthcare
logistics and specialized transportation operating segments
contributed to the increased profit on a consolidated basis when
excluding the gain on step acquisition.
Total comprehensive income was $91.0
million, compared to $92.8
million, or $54.9 million
excluding the gain on step acquisition in Fiscal 2021. Total
comprehensive income differs from net income due to the acquisition
of foreign operations (Boyle Transportation and Skelton
USA), which resulted in a positive
foreign currency translation adjustment of $14.7 million in Fiscal 2022 compared to
$2.9 million in Fiscal 2021.
EBITDA¹ totaled $174.5 million
compared with $157.2 million, or
$119.3 million excluding the gain on
step acquisition in Q4 2021. The increase (when excluding the gain
on step acquisition) is due to the factors discussed above and
reflects the incremental contributions from acquisitions and
organic growth in both of the Company's operating segments. EBITDA
Margin¹ was 26.9%, compared to 35.7%, or 27.1% excluding the gain
on step acquisition in Q4 2021.
Dividend
The Company paid a dividend (encompassing the period from
October 1, 2022 to December 31, 2022) in the amount of $0.07 per subordinate voting share and multiple
voting share on January 16, 2023.
Subject to financial results, capital requirements, available
cash flow, corporate law requirements and any other factors that
AHG's Board of Directors may consider relevant, it is the Company's
intention to declare a quarterly dividend of $0.08 per subordinate voting share and multiple
voting share on an ongoing basis.
Shares Outstanding
As at December 31, 2022, there
were 20,074,253 subordinate voting shares and 21,840,000 multiple
voting shares issued and outstanding.
Financial Statements
AHG's audited consolidated financial statements and related
Management's Discussion & Analysis ("MD&A") for Fiscal 2022
are available on the Company's website at
www.andlauerhealthcare.com and on the Company's profile on
SEDAR at www.sedar.com.
Conference call and webcast
Michael Andlauer, Chief Executive
Officer, and Peter Bromley, Chief
Financial Officer, will host a conference call for analysts and
investors on Friday, March 3, 2023 at
8:30 a.m. (ET).
To join the conference call without operator assistance, you may
register and enter your phone number at:
https://bit.ly/3R8X3MG to receive an instant automated call back.
Alternatively, you can dial (416) 764-8650 or (888) 664-6383 to
reach a live operator that will join you into the call.
You can access a live webcast of the call under the
Presentations & Events section of AHG's investor website at:
www.andlauerhealthcare.com/andlauer-healthcare-presentations-events
To access a replay of the conference call, dial 416-764-8677 or
(888) 390-0541, passcode: 172834 #. The replay will be available
until March 10, 2023. The webcast
will be archived on the Company's website following conclusion of
the call.
About AHG
AHG is a leading and growing supply chain management company
offering a robust platform of customized third-party logistics
("3PL") and specialized transportation solutions for the healthcare
sector. The Company's 3PL services include customized logistics,
distribution and packaging solutions for healthcare manufacturers
across Canada. AHG's specialized
transportation services in Canada,
including air freight forwarding, ground transportation, dedicated
delivery and last mile services, provide a one-stop shop for
clients' healthcare transportation needs. Through its complementary
service offerings, available across a coast-to-coast distribution
network, AHG strives to accommodate the full range of its clients'
specialized supply chain needs on an integrated and efficient
basis. The Company also provides specialized ground transportation
services, primarily to the healthcare sector, across the 48
contiguous U.S. states. For more information on AHG, please visit:
www.andlauerhealthcare.com.
Forward-looking Information
This news release contains forward-looking information and
forward-looking statements (collectively, "forward-looking
information") within the meaning of applicable securities laws.
Forward-looking information may relate to the Company's future
financial outlook and anticipated events or results and may include
information regarding the Company's financial position, business
strategy, growth strategies, addressable markets, budgets,
operations, financial results, taxes, dividend policy, plans,
objectives and expectations with respect to COVID-19. Particularly,
information regarding the Company's growth expectations,
performance, achievements, payment of dividends, prospects, service
expansions, potential acquisitions, financial targets or outlook,
intentions, opportunities or the potential impact of, and response
measures to be taken with respect to, COVID-19, including
expectations with respect to the distribution of COVID-19 vaccines
and ancillary products, is forward-looking information. In some
cases, forward-looking information can be identified by the use of
forward-looking terminology such as "plans", "targets", "expects",
"budget", "scheduled", "estimates", "outlook", "forecasts",
"projection", "prospects", "strategy", "intends", "anticipates",
"believes", "commencing" or variations of such words and phrases or
statements that certain actions, events or results "may", "could",
"would", "might", "will", "will be taken", "occur" or "be
achieved". In addition, any statements that refer to expectations,
intentions, projections or other characterizations of future events
or circumstances contain forward-looking information. Statements
containing forward-looking information are not historical facts but
instead represent management's expectations, estimates and
projections regarding future events or circumstances. Such
forward-looking statements are qualified in their entirety by the
inherent risks, uncertainties and changes in circumstances
surrounding future expectations which are difficult to predict and
many of which are beyond the control of the Company.
Forward-looking information is necessarily based on a number
of opinions, estimates and assumptions, including but not limited
to those assumptions described under the heading "Cautionary Note
Regarding Forward-Looking Information" in the Company's MD&A
for the year ended December 31, 2022.
Forward-looking information is subject to known and unknown risks,
uncertainties, assumptions and other factors that may cause the
actual results, level of activity, performance or achievements to
be materially different from those expressed or implied by such
forward-looking information, including but not limited to factors
discussed under the heading "Risk Factors" in the Company's annual
information form dated March 2, 2023,
which is available on the Company's profile on SEDAR at
www.sedar.com. If any of these risks or uncertainties materialize,
or if the opinions, estimates or assumptions underlying the
forward-looking information prove incorrect, actual results or
future events might vary materially from those anticipated in the
forward-looking information. Accordingly, investors should not
place undue reliance on forward-looking information, which speaks
only as of the date made. The forward-looking information contained
in this news release represents the Company's expectations as of
the date of this news release, and are subject to change after such
date and the Company disclaims any intention or obligation or
undertaking to update or revise any forward-looking information
whether as a result of new information, future events or otherwise,
except as required under applicable securities laws.
(1) Non-IFRS Financial Measures
This news release contains
certain non-IFRS measures. These measures are not recognized measures under
IFRS, do not have a standardized meaning prescribed by IFRS and are
therefore unlikely to be comparable to similar measures presented
by other companies. Rather, these measures are provided as
additional information to complement those IFRS measures by
providing further understanding of the Company's results of
operations from management's perspective. Accordingly, these
measures should not be considered in isolation nor as a substitute
for analysis of the Company's financial information reported under
IFRS. AHG uses non-IFRS measures including "EBITDA" and "EBITDA
Margin". These non-IFRS measures are used to provide investors with
supplemental measures of the Company's operating performance and
thus highlight trends in its core business that may not otherwise
be apparent when relying solely on IFRS financial measures. AHG
also believes that securities analysts, investors and other
interested parties frequently use non-IFRS measures in the
evaluation of issuers. AHG management also uses non-IFRS measures
in order to facilitate operating performance comparisons from
period to period, to prepare annual operating budgets and to
determine components of management compensation.
EBITDA
AHG defines EBITDA as net income for the period before: (i)
income tax expense (recovery); (ii) interest income; (iii) interest
expense; and (iv) depreciation and amortization.
AHG believes EBITDA is a useful measure to assess the
Company's financial performance because it provides a more relevant
picture of operating results by excluding the effects of expenses
that are not reflective of the Company's underlying business
performance.
EBITDA Margin
AHG defines EBITDA Margin as EBITDA divided by revenue.
EBITDA Margin represents a measure of the Company's
profitability expressed as a percentage of revenue.
AHG believes EBITDA Margin is a useful measure to assess the
Company's financial performance because it helps
quantify the Company's ability to convert revenues generated from
clients into EBITDA.
Gain on Step Acquisition
In this news release, AHG has adjusted EBITDA and EBITDA
Margin for the step acquisition. As set out in note 5 to AHG's
audited consolidated financial statements for Fiscal 2022, AHG
completed its acquisition of Skelton USA in two steps (49% on March 1, 2021 and the remaining 51% on
November 1, 2021). Accordingly, AHG
remeasured its previously held equity interest in Skelton
USA at its estimated fair value on
November 1, 2021 resulting in a gain
of $37.9 being recognized from the
step acquisition. AHG has presented EBITDA and EBITDA Margin
excluding the step acquisition given the one-time, non-recurring
nature of the step acquisition.
Reconciliation of EBITDA
($CAD
000s)
|
Three Months
Ended
December 31,
|
Year Ended
December 31,
|
|
2022
|
2021
|
2022
|
2021
|
2020
|
Net
income
|
19,824
|
53,104
|
76,275
|
89,954
|
37,714
|
Income tax
expense
|
6,934
|
5,371
|
27,483
|
18,486
|
8,866
|
Interest
expense
|
1,867
|
1,565
|
6,858
|
6,219
|
4,595
|
Interest
income
|
(396)
|
(32)
|
(599)
|
(198)
|
(285)
|
Depreciation and
amortization
|
16,455
|
13,683
|
64,452
|
42,716
|
28,022
|
EBITDA1
|
44,684
|
73,691
|
174,469
|
157,177
|
78,912
|
Gain on step
acquisition of equity-
accounted investee
|
-
|
(37,921)
|
-
|
(37,921)
|
-
|
EBITDA1
excluding gain on step acquisition
|
44,684
|
35,770
|
174,469
|
119,256
|
78,912
|
SOURCE Andlauer Healthcare Group Inc.